Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing
As a fully integrated gene therapy company, Capsida is unique in its end-to-end expertise which includes AAV engineering, cargo development and optimization, translational biology, early capsid manufacturability, clinical development, and state-of-the-art manufacturing.
- As a fully integrated gene therapy company, Capsida is unique in its end-to-end expertise which includes AAV engineering, cargo development and optimization, translational biology, early capsid manufacturability, clinical development, and state-of-the-art manufacturing.
- "One of our key strategic priorities at Capsida is to create therapies that can be manufactured consistently and rapidly while maintaining the highest quality," said Rayne Waller, chief manufacturing officer of Capsida Biotherapeutics.
- "Our new manufacturing facility eliminates the dependence on contract manufacturing which will allow us to bring products seamlessly from discovery into clinical studies faster.
- Capsida Biotherapeutics Inc. is developing tissue-targeted gene therapies using its biologically driven, high-throughput adeno-associated virus (AAV) engineering and proprietary cargo development platform.